Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Impact of intraoperative adverse events during branched and fenestrated aortic stenting grafting on postoperative outcome

Frédéric Cochennec, MD, a Hicham Kobeiter, MD, b Manj S. Gohel, MD, c Marek Majewski, MD, c Jean Marzelle, MD, a Pascal Desgranges, MD, a Eric Allaire, MD, PhD, a and Jean Pierre Becquemin, MD, a Créteil, France; and Cambridge, United Kingdom

Objective: Fenestrated and branched endovascular devices are increasingly used for complex aortic diseases, and despite the challenging nature of these procedures, early experiences from pioneering centers have been encouraging. The objectives of this retrospective study were to report our experience of intraoperative adverse events (IOAEs) during fenestrated and branched stent grafting and to analyze the impact on clinical outcomes.

Methods: Consecutive patients treated with fenestrated and branched stent grafting in a tertiary vascular center between February 2006 and October 2013 were evaluated. A prospectively maintained computerized database was scrutinized and updated retrospectively. Intraoperative angiograms were reviewed to identify IOAEs, and adverse events were categorized into three types: target vessel cannulation, positioning of graft components, and intraoperative access. Clinical consequences of IOAEs were analyzed to ascertain whether they were responsible for death or moderate to severe postoperative complications.

Results: During the study period, 113 consecutive elective patients underwent fenestrated or branched stent grafting. Indications for treatment were asymptomatic complex abdominal aortic aneurysms (CAAAs, n = 89) and thoracoabdominal aortic aneurysms (TAAAs, n = 24). Stent grafts included fenestrated (n = 79) and branched (n = 17) Cook stent grafts (Cook Medical, Bloomington, Ind), Ventana (Endologix, Irvine, Calif) stent grafts (n = 9), and fenestrated Anaconda (Vascutek Terumo, Scotland, UK) stent grafts (n = 8). In-hospital mortality rates for the CAAA and TAAA groups were 6.7% (6 of 99) and 12.5% (3 of 24), respectively. Twenty-eight moderate to severe complications occurred in 21 patients (18.6%). Spinal cord ischemia was recorded in six patients, three of which resolved completely. A total of 17 IOAEs were recorded in 14 (30.1%) patients (22 CAAAs and 12 TAAAs). Of 17 IOAEs, 15 (40.5%) resulted in no clinical consequence in 15 patients; 17 (45.9%) were responsible for moderate to severe complications in 16 patients, and five (13.5%) led to death in four patients. The composite end point death/nonfatal moderate to severe complication occurred more frequently in patients with IOAEs compared with patients without IOAEs (20 of 34 vs 12 of 79; P < .0001).

Conclusions: In this contemporary series, IOAEs were relatively frequent during branched or fenestrated stenting procedures and were often responsible for significant complications. (J Vasc Surg 2014;60:571-8.)

Fenestrated and branched endovascular aneurysm repairs (FEVAR and BEVAR) have become an attractive alternative to open repair for complex abdominal aortic aneurysms (CAAAs) and thoracoabdominal aortic aneurysms (TAAAs). In many countries, these complex procedures are still under evaluation and generally available only in tertiary centers. In France, fenestrated and branched Cook devices have been approved for reimbursement from the national health care system. However, intraoperative difficulties and complications are not rare. Safe target vessel cannulation and stenting is a concern, particularly in the presence of stenotic ostial lesions and small or angulated target vessels. Malpositioning of stent graft components can also have devastating consequences. As delivery devices are larger than in standard infrarenal endovascular aneurysm repair (EVAR) and the procedure duration is generally longer, patients are more prone to access complications. The real incidence of those intraoperative adverse events (IOAEs) and their impact on the postoperative course are poorly documented.

In this retrospective study, we report the incidence of IOAEs during fenestrated or branched stent grafting and analyze to what extent these adverse events may influence early postoperative outcomes.

METHODS

Study setting. Consecutive patients undergoing FEVAR or BEVAR between February 2006 and October 2013 in a tertiary vascular unit (Henri Mondor Hospital, Créteil) were included. Patients were treated for CAAAs and TAAAs. CAAAs included short-necked infrarenal,
juxtarenal, pararenal, and suprarenal abdominal aortic aneurysms, considered unsuitable for conventional EVAR. TAAAs were classified according to the Crawford classification. In our institution, all patients with CAAAs and TAAAs are considered for open, hybrid, or endovascular repair in a multidisciplinary meeting including vascular surgeons, interventional radiologists, and anesthesiologists. Demographic, anatomic, intraoperative, and postoperative data were recorded by means of a prospectively collected database.

Preoperative assessment and device sizing. All patients underwent a high-resolution computed tomography scan preoperatively and before discharge. Procedure planning and device sizing were performed with a dedicated three-dimensional vascular imaging workstation (Aquarius WS; TeraRecon Inc, Mateo, Calif) with centerline luminal reconstructions. The aneurysm morphology was assessed by a vascular surgeon (M.M.) and an interventional radiologist (H.K.), both with considerable experience with EVAR.

Device designs proposed by the implanting physicians were systematically reviewed and approved by the planning center of the corresponding device manufacturer.

Details of procedures. Procedures were performed in an angiography suite (Philips FD20; Philips Healthcare, Cleveland, Ohio) in a sterile environment. An experienced proctor physician was present during the procedure for the first five Cook fenestrated cases, the first two Cook branched cases, and the first fenestrated Anaconda and Ventana cases. Eight physician-modified fenestrated stent grafts were excluded. For each device, the implantation techniques have been described previously.

Control angiograms were obtained once each target vessel was cannulated with a long sheath, after deployment of bridging covered stents in each target vessel, and at the end of the procedure. Each control angiogram was saved and images were stored in a database. Technical problems and subsequent IOAEs were also recorded in the database.

Definitions. IOAEs were defined as any intraoperative complication or technical problem occurring during stent graft implantation that required additional and unexpected endovascular manipulations. IOAEs were classified in three distinct types:

- **Type 1:** Problems with target vessel cannulation;
- **Type 2:** Malpositioning of one of the following graft components: bridging stents, bifurcated component, or iliac extensions; and
- **Type 3:** Difficulty with intraoperative access.

Complications were defined according to the Society for Vascular Surgery criteria. Only moderate and severe complications were reported in the current series.

### Table I. Clinical and anatomic data

|                         | CAAA (n = 89) | TAAA (n = 24) | Overall (N = 113) |
|-------------------------|--------------|--------------|------------------|
| **Clinical data**       |              |              |                  |
| Males                   | 80 (90)      | 21 (87)      | 101 (89)         |
| Age, years              | 73 ± 9       | 72 ± 9       | 73 ± 9           |
| Diabetes mellitus       | 17 (19)      | 2 (8)        | 19 (17)          |
| Tobacco use in last 10 years | 52 (58)    | 15 (62)      | 67 (59)          |
| Hypertension            | 62 (70)      | 17 (71)      | 79 (70)          |
| Hyperlipidemia          | 46 (52)      | 10 (42)      | 56 (50)          |
| Coronary artery disease | 46 (52)      | 7 (29)       | 53 (47)          |
| Myocardial infarction   | 21 (24)      | 3 (12)       | 25 (22)          |
| Congestive heart failure| 22 (25)      | 8 (33)       | 30 (27)          |
| Arrhythmia              | 14 (16)      | 3 (12)       | 17 (15)          |
| Cerebrovascular disease | 19 (21)      | 1 (4)        | 20 (18)          |
| Chronic renal insufficiency | 17 (19)   | 4 (17)       | 21 (19)          |
| Pulmonary disease       | 35 (39)      | 9 (37)       | 44 (39)          |
| Peripheral vascular disease | 13 (15)   | 4 (17)       | 17 (15)          |
| Cancer                  | 14 (16)      | 5 (21)       | 19 (17)          |
| Obesity                 | 18 (20)      | 3 (12)       | 21 (19)          |
| **Anatomic data**       |              |              |                  |
| Maximal diameter, mm    | 59 ± 10      | 60 ± 10      | 59 ± 10          |
| Type of aneurysm        |              |              |                  |
| Short neck/juxtarenal   | 63 (71)      |              |                  |
| Pararenal               | 20 (22)      |              |                  |
| Suprarenal              | 6 (7)        |              |                  |
|                       | CAAA, Complex abdominal aortic aneurysm; TAAA, thoracoabdominal aortic aneurysm. Continuous data are presented as mean ± standard deviation and categorical data as number (%).

### Table II. Details of stent graft configurations

| Stent graft configuration | No. (%) |
|---------------------------|---------|
| Fenestrated stent grafts  | 96 (85) |
| One fenestration          | 4 (4)   |
| Two fenestrations         | 43 (38) |
| Three fenestrations       | 36 (32) |
| Four fenestrations        | 13 (12) |
| Branched stent grafts     | 11 (10) |
| Three branches            | 1 (1)   |
| Four branches             | 10 (9)  |
| Stent grafts with fenestrations and branches | 6 (5) |
| Three target vessels      | 1 (1)   |
| Four target vessels       | 5 (4)   |

Device designs proposed by the implanting physicians were systematically reviewed and approved by the planning center of the corresponding device manufacturer.
### Table III. Details of patients who died during the postoperative course

| Gender | Age, Years | ASA class | Anatomic details and expected technical difficulties | Stent graft | Details of IOAE | Cause of death |
|--------|------------|-----------|------------------------------------------------------|-------------|----------------|----------------|
| Patient 55 | M | 65 | Type IV TAAA >50% stenoses of RRA, LRA, and right CIA Shaggy aorta | 4 fenestrations, Cook | RRA and LRA cannulation failure Graft limb occlusion requiring bilateral thrombectomy and iliofemoral bypasses | Paraplegia, renal failure, pneumonia |
| Patient 74 | M | 78 | Type III TAAA >45-degree aortic angulation >50% stenosis of the CT Two accessory renal arteries Severe iliac tortuosity | 4 visceral branches, one additional branch for temporary elective sac perfusion to prevent spinal cord ischemia, Cook | Sizing error: additional branch placed at the level of overlap between two components | Paraplegia, meningocerebralitis after spinal drain placement |
| Patient 80 | F | 71 | Justarenal AAA >50% stenosis of SMA Narrowed infrarenal aorta (<18 mm) Short occlusion of left CIA Sharp angulation of aortic bifurcation | 3 fenestrations, Anaconda | Sizing error RRA cannulation failure and difficult cannulation of SMA | Bowel ischemia due to SMA stent occlusion MOSF despite splenic artery to SMA transposition |
| Patient 95 | M | 82 | Shaggy aorta | 3 fenestrations, Cook | SMA cannulation failure requiring a bailout chimney stent for the SMA | Cholesterol embolism syndrome, bowel ischemia SMA and CT patent on control computed tomography scan |
| Patient 30 | M | 76 | Justarenal AAA Shaggy aorta Narrowed infrarenal aorta (<18 mm) | 4 fenestrations, Cook | No IOAE | Cholesterol embolism syndrome, bowel ischemia SMA and CT patent on control computed tomography scan |
| Patient 39 | M | 82 | Justarenal AAA Floating thrombus in the visceral aorta, severe iliac tortuosity | 3 fenestrations, Cook | No IOAE | Cholesterol embolism syndrome, bowel ischemia SMA and CT patent on control computed tomography scan |
| Patient 42 | M | 71 | Suprarenal AAA Narrowed infrarenal aorta (<18 mm) | 3 fenestrations, aortouniliac device for narrowed aortic bifurcation, Cook | No IOAE but long procedure | Femorofemoral prosthetic graft infection Developed MOSF despite prosthetic graft replacement by a venous graft |
| Patient 49 | M | 76 | Justarenal AAA Small (<5 mm) LRA | 3 fenestrations, Cook | No IOAE | Pneumonia, SARS |
| Patient 65 | M | 63 | Type IV TAA | 4 fenestrations, Cook | No IOAE | Bowel ischemia, unexplained occlusion of SMA and CT stents at day 1 Developed MOSF despite successful SMA stent thrombectomy and colonic and bowel resection |

AAA, Aortic abdominal aneurysm; ASA, American Society of Anesthesiologists; CIA, common iliac artery; CT, celiac trunk; EIA, external iliac artery; F, female; IOAE, intraoperative adverse event; LRA, left renal artery; M, male; MOSF, multiorgan system failure; RRA, right renal artery; SARS, severe acute respiratory syndrome; SMA, superior mesenteric artery; TAAA, thoracoabdominal aneurysm.

**Study protocol.** A radiologist (H.K.) and a vascular surgeon (F.C.) reviewed intraoperative and postoperative data recorded in the prospectively maintained FEVAR or BEVAR database and all intraoperative angiograms for each patient to identify IOAEs. Both clinicians also participated in the majority of the procedures.

To evaluate the clinical consequences of IOAEs for postoperative outcome, the composite end point
death/nonfatal moderate to severe complication was determined for patients with and without IOAEs. Because this present study focused only on short-term follow-up, endoleaks identified on control angiograms or on postoperative computed tomography scans were not considered IOAEs or complications.

RESULTS

Patient population. During the 7½ year study period, 113 consecutive elective patients underwent FEVAR or BEVAR. No fenestrated or branched devices were implanted to treat infected or ruptured aneurysms. All patients were deemed at high risk for open repair. Demographic and anatomic data are presented in Table I.

Device implantation. Stents implanted in this study population were fenestrated or branched Cook (Cook Medical, Bloomington, Ind) stents in 96 of 113 (85%), Ventana (Endologix, Irvine, Calif) stents in 9 of 113 (8%) cases, and Anaconda (Vascutek Terumo, Scotland, UK) stents in 8 of 113 (7%) cases. For CAAAs, there were no specific criteria for choosing which stent to use. Choice was made according to the surgeon’s preference. For TAAAs, we used the Cook device. Details of stent graft design and number of fenestrations and branches are detailed in Table II. The mean (standard deviation) number of target vessels per patient was 2.8 ± 0.8.

Clinical outcomes and IOAEs. The overall inhospital mortality was 8.0% (9 of 113 patients). In-hospital mortality rates for the CAAA and TAAA groups were 6.7% (6 of 89) and 12.5% (3 of 24), respectively (Table III). A total of 28 moderate to severe complications occurred in 21 (18.6%) patients (Table IV); 17 complications were related to IOAEs, and 11 occurred without any IOAE. In patients with TAAAs, complete paraplegia occurred in three cases (12.5%). Two other patients presented with paraparesis that resolved completely after spinal fluid drainage. In the CAAA group, one patient with a juxtarenal aneurysm who underwent fenestrated stent grafting with three fenestrations presented with hypotension of both limbs that resolved completely after spinal fluid drainage.

A total of 37 IOAEs were recorded in 34 (30.1%) patients (22 CAAAs and 12 TAAAs). Of 37 IOAEs, 15 (40.5%) resulted in no clinical consequence in 15 patients; 17 (45.9%) were responsible for moderate to severe complications in 16 patients, and five (13.5%) were directly or indirectly responsible for death in four patients. The composite end point death/nonfatal moderate to severe complication occurred more frequently in patients with IOAEs compared with patients without IOAEs (20 of 34 vs 12 of 79; P < .0001, χ² test). IOAEs occurred in 22 of 89 (25%) CAAA patients compared with 12 of 24 (50%) TAAA patients (P = .02, χ² test). IOAEs occurred in 24 of 96 patients (25%) who underwent a fenestrated stent graft compared with 10 of 17 patients (58.9%) who underwent a branched stent graft (P = .005, χ² test). In both those groups, difficulty with target vessel cannulation (type 1 IOAE) was the most frequent (Table V). The incidence of IOAEs was not significantly different in patients who underwent a Cook fenestrated stent graft compared with patients who underwent an Anaconda or a Ventana fenestrated stent graft. The incidence of IOAE did not change over time (Fig).

Type 1 IOAEs (problems with target vessel cannulation) occurred in 22 of 113 cases (19.4%), resulting in death (n = 3) or moderate to severe complication (n = 10) in 13 patients (59.1%). They led to target vessel loss in five cases (22.7%). Details of type 1 IOAEs, intraoperative management, and related outcomes are given in Table VI.

Type 2 IOAEs (malpositioning of one of the graft components) occurred in 5 of 113 cases (4.4%), resulting in death or complication in two patients (Table VII).

Type 3 IOAEs (related to access site problems) occurred in 10 of 113 patients (8.8%), leading to early postoperative death in one patient and moderate to severe complications in another six patients (Table VIII).

DISCUSSION

The utility of fenestrated and branched devices for the treatment of CAAAs and TAAAs has gained widespread acceptance, with several large series confirming satisfactory early and midterm results.5,11-18 In a recent systematic review of juxtarenal abdominal aortic aneurysms treated by FEVAR,16 368 FEVAR cases from eight cohort studies were evaluated. The reported 30-day mortality was 1.4%, and the incidence of permanent renal dialysis was 1.4%. Data from national registries and from high-volume centers have provided similar results, with 30-day mortality rates varying from 2% to 4%.13,14,17 In expert hands, endovascular repair of TAAA with FEVAR or BEVAR has been associated with encouraging short-term results, with 30-day mortality ranging from 5% to 12% and spinal cord ischemia from 3% to 17%.4,12,18,20

Table IV. Nonfatal early postoperative moderate to severe complications

| Moderate to severe nonfatal complications | N = 28 in 21 patients (18.6%) |
|-----------------------------------------|--------------------------------|
| Systemic                                |                                 |
| Renal insufficiency                     | 9                               |
| Spinal cord injury                      | 4                               |
| Complete                                | 1                               |
| Transient                               | 3                               |
| Stroke                                  | 1                               |
| Colonic ischemia                        | 1                               |
| Deployment/implant-related complications|                                 |
| Access artery thrombosis                | 5                               |
| Cholesterol embolism syndrome           | 2                               |
| Arterial perforation                    | 1                               |
| Access site lymphorrhoea                | 1                               |
| Access site hematoma                    | 2                               |
| Acute limb compartment syndrome         | 1                               |
| Complications related to IOAE           | 17                              |
| Complications unrelated to IOAE         | 11                              |

IOAE, Intraoperative adverse event; SMA, superior mesenteric artery.
Table V. Incidence of intraoperative adverse events (IOAEs) according to the type of stent graft

| Patients presenting with IOAE | F grafts, Cook F | Ventana F | Anaconda F | All F grafts | B grafts, Cook B | Cook F vs Anaconda F | Cook F vs Ventana F | All F grafts vs B Cook |
|-----------------------------|-----------------|-----------|------------|--------------|-----------------|---------------------|---------------------|----------------------|
| Type 1 IOAE                 | 10 (12.7)       | 2 (22.2)  | 2 (25)     | 14 (14.6)    | 8 (47.1)        | .3                   | .6                   | 1                    | .002                 |
| Type 2 IOAE                 | 4 (5.1)         | 0         | 0          | 4 (4.2)      | 1 (5.9)         | 1                   | 1                   | 1                    | .6                   |
| Type 3 IOAE                 | 8 (10.1)        | 0         | 0          | 8 (8.3)      | 2 (11.8)        | 1                   | 1                   | 1                    | .7                   |
| Any type of IOAE            | 20 (25.3)        | 2 (22.2)  | 2 (25.0)   | 24 (25.0)    | 10 (58.9)       | 1                   | 1                   | 1                    | .005                 |

B, Branched or branched and fenestrated grafts; F, fenestrated; type 1 IOAE, problems with target vessel cannulation; type 2 IOAE, malpositioning of one of the nonfenestrated graft components (bridging stents, bifurcated component, or iliac extensions); type 3 IOAE, difficulty with intraoperative access.

Data are presented as number (%).

\*Fisher exact test or \( \chi^2 \) test.

\( b \) Two patients presented with two types of IOAE.

\( c \) One patient presented with two types of IOAE.

With 30-day mortality rates of 6.7% for juxtarenal patients and 12.5% for TAAA patients, our results do not compare favorably with previously published data. Several reasons might explain this observation. In contrast with pioneering series, in which one physician performed the majority of the cases, two vascular surgeons in our institution performed fenestrated and branched procedures as the first operator, although a highly experienced interventional radiologist (H.K.) was present during almost all procedures. This, combined with the fact that three different types of device were used, might have contributed to IOAEs in some patients. However, more than a simple learning curve of technical skills, one could argue that our results are mainly due to suboptimal patient selection. On review of the mortalities in this series, all patients had challenging aneurysm morphology or significant comorbidity (American Society of Anesthesiologists class 4). Four patients had “shaggy” aortas with floating thrombus, resulting in fatal embolic complications. As FEVAR and BEVAR are being increasingly used and disseminated, the results of our initial experience confirm that they remain complex procedures that need to be centralized in high-volume centers. They also raise the question of whether encouraging results of initial series can be reproduced in the “real world,” knowing these series came from a very few pioneering expert centers and included highly selected patients.

Type 1 IOAEs (problems with target vessel cannulation) were the most frequent in our experience (n = 22). Target vessel occlusions and dissections occurred in 11 cases and were mainly due to target vessel injury or thrombus formation in the long 7F sheaths. Even if most of them could be rescued with additional bailout endovascular maneuvers and without permanent damaging consequences for the patient (Table VI), they are considered avoidable. Thrombus formation in the long 7F sheaths may also have been avoided by more frequent flushing. Cannulation failure was relatively rare (n = 4) but had devastating consequences for the patient, leading directly or indirectly to severe complications or death (Table VI). This was mainly due to sizing errors, malpositioning of the fenestrated component, or difficult anatomy and occurred predominantly at the beginning of our experience.

Type 2 IOAEs (malpositioning of bridging stents, bifurcated component, or iliac extensions) are also considered avoidable technical errors. In our series, they occurred in five cases. In one patient with a type II TAAA, a sac perfusion branch had to be covered as it was inadvertently located at an overlap zone. The patient subsequently died of meningoencephalitis after spinal drain placement for paraplegia, although the use of sac perfusion branches to reduce paraplegia risk remains controversial. With the exception of one endovascular reintervention, all remaining IOAEs relating to graft malpositioning were managed successfully without harm to the patient.

FEVAR and BEVAR procedures are frequently long, require large-diameter introducer sheaths, and are prone to access vessel complications. In this series, intraoperative access site problems (type 3 IOAEs) occurred in 10 patients (8.8%), leading to moderate or severe complications in seven cases. In our current practice, we use a
percutaneous approach for most standard EVAR cases. Because of the increased risk of access complications during FEVAR and BEVAR procedures, we still favor surgical cut-down of femoral arteries.

Caution should be taken in interpreting the results of this series as the definition of CAAA is broad, including short neck, juxtarenal, pararenal, and suprarenal aneurysms. Consequently, there was considerable heterogeneity in complexity of aneurysm morphology and difficulty of procedures, which varied from stents with two fenestrations to challenging branched stent grafting for type II TAAAs in high-risk patients. Despite these limits, this study

Table VI. Details of type 1 intraoperative adverse events (IOAEs) (problems with target vessel cannulation) and clinical consequences

| Type of IOAE                  | Number of events (n = 22) | Intraoperative treatment                                      | Consequences for target vessel and related outcomes | Clinical outcomes                        |
|-------------------------------|---------------------------|--------------------------------------------------------------|----------------------------------------------------|-----------------------------------------|
| RA occlusion or dissection    | 10                        | Thrombolysis: 4                                              | Remained patent: 8                                 | Dialysis: 1                             |
|                               |                           | Thrombolysis and thromboaspiration: 2                        |                                                   | Permanently reduced renal function: 1   |
|                               |                           | Thrombolysis and additional stent placement: 2             |                                                   | Temporarily reduced renal function: 1   |
| SMA dissection                | 2                        | Additional stent placement: 2                               |                                                   | No impact on renal function: 4          |
| RA cannulation failure        | 3                        | Additional stent placement: 2                               | Remained patent                                   | Permanently reduced renal function: 1   |
| SMA cannulation failure       | 3                        | Additional stent placement: 2                               | Target vessel lost: 2                              | Temporarily reduced renal function: 1   |
| RA rupture                    | 2                        | Bailout chimney stent                                        | Remained patent                                   | Death                                   |
| Other difficulties during     | 2                        | Additional stent placement: 1                               | Remained patent                                   | Asymptomatic                            |
| target vessel cannulation     |                           | Distal coil embolization: 1                                 |                                                   |                                        |
| Difficult cannulation of both | 2                        | —                                                            | Remained patent                                   |                                        |
| RAs                           |                           | —                                                            | Partial covering of the SMA                       |                                        |
| Mispositioning of a scallop   | 2                        | —                                                            | Remained patent                                   |                                        |
| dedicated to SMA              |                           | —                                                            | Reintervention for SMA stenting                   |                                        |
| Scallop deployed in posterior | 2                        | —                                                            | Remained patent                                   |                                        |
| position                       |                           | —                                                            | Asymptomatic                                       |                                        |
| Two stents for two right RA   | 2                        | —                                                            | Remained patent                                   |                                        |
| RAs in the same fenestration  |                           | —                                                            | Partial covering of the SMA                       |                                        |
| RRA stented through a scallop | 2                        | —                                                            | Reintervention for SMA stenting                   |                                        |
| dedicated to SMA              |                           | —                                                            | Asymptomatic                                       |                                        |

RA, Renal artery; RRA, right renal artery; SMA, superior mesenteric artery.

Table VII. Details of type 2 intraoperative adverse events (IOAEs) (malpositioning of one of the nonfenestrated graft components) and clinical consequences

| Details of graft component malpositioning                             | Clinical outcomes                                      |
|-----------------------------------------------------------------------|--------------------------------------------------------|
| Sizing error leading to malpositioning and coverage of an additional  | Paraplegia, meningoencephalitis after spinal drain      |
| branch for temporary elective sac perfusion to prevent spinal cord    | placement, death                                       |
| ischemia                                                              | Early occlusion of SMA stent, bowel ischemia           |
| Inadequate positioning of SMA stent, long portion remaining in the    | Successful endovascular stent removal, placement of     |
| aortic lumen                                                          | another stent                                          |
| Right graft limb disconnection requiring placement of an additional   | None                                                   |
| graft limb                                                            | Unintentional coverage of the LIIA                     |
| Unintentional coverage of the RIIA                                    | None                                                   |
| Unintentional coverage of the RIIA                                    | None                                                   |

LIIA, Left internal iliac artery; RIIA, right internal iliac artery; SMA, superior mesenteric artery.
suggestions that in routine practice, technical difficulties and IOAEs during FEVAR and BEVAR procedures are not rare, particularly with difficult aneurysm morphology. It is likely that continuous improvements in endovascular and imaging technologies will improve the safety of complex endovascular aortic procedures. Development of lower profile stent grafts and bridging stents, with better visibility and repositionability, will probably play a key role in reducing IOAEs. New tools for improved catheter navigation, such as robotic navigation,21 may also facilitate target vessel cannulation. Although few data exist, fusion of images may be useful to reduce doses of contrast material and radiation.22

CONCLUSIONS

In our series, IOAEs during branched and fenestrated stent grafting were frequent, occurring in 25% of patients with CAAAs and 50% of patients with TAAAs. As branched and fenestrated devices are being increasingly used and disseminated in vascular centers, additional studies are needed to determine if the encouraging results from pioneering expert centers can be reproduced in “real-life” practice.

AUTHOR CONTRIBUTIONS

Conception and design: FC, HK
Analysis and interpretation: FC, HK, MG
Data collection: FC, HK, MM, PD, EA, JM, JPB
Writing the article: FC, MG
Critical revision of the revision: FC, JM, JPB
Final approval of the article: FC, HK, MM, MG, PD, EA, JM, JPB
Statistical analysis: FC, HK
Obtained funding: Not applicable
Overall responsibility: FC, JPB

REFERENCES

1. Resch T, Sonesson B, Malina M. Incidence and management of complications after branched and fenestrated endografting. J Cardiovasc Surg (Torino) 2010;51:105-13.
2. Crawford ES, Crawford JL, Safi HJ, Coselli JS, Hess KR, Brooks B, et al. Thoracoabdominal aortic aneurysms: preoperative and intraoperative factors determining immediate and long-term results of operations in 605 patients. J Vasc Surg 1986;3:389-404.
3. Anderson JL, Adam DJ, Berce M, Hartley DE. Repair of thoracoabdominal aortic aneurysms with fenestrated and branched endo-stent grafts. J Vasc Surg 2005;42:600-7.
4. Haulon S, D’Elia P, O’Brien N, Sobocinski J, Perrot C, Lerussi G, et al. Endovascular repair of thoracoabdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2010;39:171-8.
5. O’Neill S, Greenberg RK, Haddad F, Resch T, Sereika J, Katz E. A prospective analysis of fenestrated endovascular grafting: intermediate-term outcomes. Eur J Vasc Endovasc Surg 2006;32:115-23.
6. Scurr JR, Brennan JA, Gilling-Smith GL, Harris PL, Vallabhaneni SR, McWilliams RG. Fenestrated endovascular repair for juxtarenal aortic aneurysm. Br J Surg 2008;95:326-32.
7. Semmens JB, Lawrence-Brown MM, Hartley DE, Allen YB, Green R, Nadkarni S. Outcomes of fenestrated endografts in the treatment of abdominal aortic aneurysm in Western Australia (1997-2004). J Endovasc Ther 2006;13:320-9.
8. Bungay PM, Burritt N, Setharan K, Muz I, Khan SL, De Nunzio MC, et al. Initial experience with a new fenestrated stent graft. J Vasc Surg 2011;54:1832-8.
9. Mertens R, Bergoeing M, Marine L, Valdes F, Kramer A, Vergara J. Venstana fenestrated stent-graft system for endovascular repair of juxtarenal aortic aneurysms. J Endovasc Ther 2012;19:173-8.
10. Chaikof EL, Blankenstein JD, Harris PL, White GH, Zarins CK, Bernhard VM, et al. Reporting standards for endovascular aortic aneurysm repair. J Vasc Surg 2002;35:1048-60.
11. Greenberg RK, Eagleton M, Mastracci T. Branched endografts for thoracoabdominal aneurysms. J Thorac Cardiovasc Surg 2010;140(Suppl):S171-8.
12. Greenberg RK, Lu Q, Roselli EE, Svensson LG, Moon MC, Hernandez AV, et al. Contemporary analysis of descending thoracic and thoracoabdominal aneurysm repair: a comparison of endovascular and open techniques. Circulation 2008;118:808-17.
13. Greenberg RK, Steinbergh WC, Srd, Makaroun M, Ohtli T, Chuter T, Bharadwaj P, et al. Intermediate results of a United States multicenter trial of fenestrated endograft repair for juxtarenal abdominal aortic aneurysm. J Vasc Surg 2009;50:730-7.e1.
14. Haulon S, Aimiot S, Magnan PE, Bocquemun JP, Lermusiaux P, Koussa M, et al. An analysis of the French multicentre experience of fenestrated endografts: medium-term outcomes. Ann Surg 2010;251:357-62.
15. Verhoeven EL, Tielliu IF, Ferreira M, Zépil B, Adam DJ. Thoracoabdominal aortic aneurysm branched repair. J Cardiovasc Surg (Torino) 2010;51:149-55.
16. Nordon IM, Hinchliffe RJ, Holt PJ, Loftus IM, Thompson MM. Modern treatment of juxtarenal abdominal aortic aneurysms with fenestrated endografting and open repair—a systematic review. Eur J Vasc Endovasc Surg 2009;38:35-41.
17. British Society for Endovascular Therapy and the Global Collaborators on Advanced Stent-Graft Techniques for Aneurysm Repair (GLOBALSTAR) Registry. Early results of fenestrated endovascular repair of juxtarenal aortic aneurysms in the United Kingdom. Circulation 2012;125:2707-15.
18. Chuter TA, Rapp JH, Hiramoto JS, Schneider DB, Howell B, Reilly LM. Endovascular treatment of thoracoabdominal aortic aneurysms. J Vasc Surg 2008;47:6-16.
19. Roselli EE, Greenberg RK, Pfaff K, Francis C, Svensson LG, Lytle BW. Endovascular treatment of thoracoabdominal aortic aneurysms. J Thorac Cardiovasc Surg 2007;133:1474-82.
20. Verhoeven EL, Tielliu IF, Bos WT, Zeebregts CJ. Present and future of branched stent grafts in thoraco-abdominal aortic aneurysm repair: a single-centre experience. Eur J Vasc Endovasc Surg 2009;38:155-61.
21. Riga CV, Cheshire NJ, Hamady MS, Bicknell CD. The role of robotic endovascular catheters in fenestrated stent grafting. J Vasc Surg 2010;51:810-9; discussion: 819-20.
22. Dijkstra ML, Eagleton MJ, Greenberg RK, Mastracci T, Hernandez A. Intraoperative C-arm cone-beam computed tomography in fenestrated/branched aortic endografting. J Vasc Surg 2011;53:583-90.

Submitted Aug 12, 2013; accepted Feb 23, 2014.

INVITED COMMENTARY

Timothy A. Resch, MD, PhD, Malmö, Sweden

The report by Dr Cochennec highlights some very significant issues related to the practice and dissemination of complex aortic procedures.

The authors present 113 cases performed during a period of 7 years, which equates to fewer than 20 cases per annum divided among four operators using three endovascular devices. Previous studies have shown a link between surgeon as well as center volumes and outcomes. Complex aneurysms represent a small proportion of all aneurysms treated, and it is difficult, even in large vascular centers, to achieve volumes large enough to reap the benefits of truly high volumes. In contrast to “simpler” aortic procedures, treatment of complex aneurysms is not only a question of individual operator experience and skill, but it places significant demands on the supporting structure of the center.

Preoperative planning of complex cases is paramount for success. Detailed anatomic analysis as well as extensive specific device knowledge is needed. The learning curve is significantly longer than for infrarenal endovascular aneurysm repair. This indicates that it is better to use a single device and to learn it well rather than to stray between different devices, trying to take advantage of individual stent graft benefits.

Certain morphologic features need to be specifically addressed. (1) A “shaggy” aorta is a risk factor for embolic events and poor outcome. (2) Poor access can lead to difficulties in orienting the device, leading to target vessel loss, resulting in end-organ dysfunction. Very long procedures can lead to compartment syndrome as well as a systemic reperfusion injury causing severe physiologic instability and multiorgan failure in the immediate postoperative phase.

 Patients with complex aneurysmal disease often carry significant comorbidities and generally have a much lower tolerance for perioperative and postoperative complications, which is clearly seen in the current study with significant morbidity and mortality. This furthermore emphasizes the need for appropriate patient selection, workup, and optimization before surgery as well as extensive involvement of anesthetic and intensive care expertise in the preoperative, perioperative, and postoperative period. This can most likely be achieved only in very select high-volume centers dedicated to treatment of complex aortic disease.

I thank the authors for their honest reporting and for highlighting the issues in dealing with complex endovascular aortic procedures.

REFERENCES

1. Thompson M, Holt P, Loftus I, Forbes TL. Debate: whether abdominal aortic aneurysm surgery should be centralized at higher-volume centers. J Vasc Surg 2011;54:1208-14.
2. Patel SD, Constantinoiu J, Hamilton H, Davis M, Ivancev K. A shaggy aorta is associated with mesenteric embolisation in patients undergoing fenestrated endografts to treat paravisceral aortic aneurysms. Eur J Vasc Endovasc Surg 2014;47:374-9.
3. Kristmundsson T, Sonesson B, Malina M, Bjorses K, Dais N, Resch T. Fenestrated endovascular repair for juxtarenal aortic pathology. J Vasc Surg 2009;49:568-74; discussion: 754-5.